Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBX2660 in Hepatic Encephalopathy
NCT03439982Phase 2Completed
- Sponsor
- University of Alberta
- Start
- Apr 2016
- Primary completion
- Aug 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of RBX2660 in hepatic encephalopathy (HE), sponsored by University of Alberta. Started Apr 2016; status: completed.
02
Drugs
RBX2660
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT03439982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439982.